Below is a three month price history chart comparing the stock performance of VRX, versus MCK and AGN.
FORBES: Top Buys by Top Brass: Chief Executive Officer Pearson's $6M Bet on VRX
2.
According to the ETF Finder at ETF Channel, VRX makes up 3.84% of the Pharmaceutical HOLDRS ETF ( AMEX: PPH) which is trading lower by about 1.4% on the day Monday.
FORBES: Top Buys by Top Brass: Chief Executive Officer Pearson's $6M Bet on VRX
3.
Valeant Pharmaceuticals (VRX) is commercializing the treatment.
FORBES: Pharma News: Alexza Pharmaceuticals, YM BioSciences